Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Common and Not-So-Common Comorbidities of PsoriasisM Alan Menter, April W Armstrong, Kenneth B Gordon, et al.
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Archives of Dermatology|December 17, 2003
Severe hidradenitis suppurativa treated with infliximab infusionDavid R Adams, Kenneth B Gordon, Attila G Devenyi, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseGerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.
Blood|May 3, 2002
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cellsAnn M Girvin, Kenneth B Gordon, C Jane Welsh, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Seminars in Cutaneous Medicine and Surgery|July 27, 2017
Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™Kenneth B Gordon, Craig L Leonardi, Daniel E Furst, et al.
Archives of Dermatology|January 19, 2005
Definitions of measures of effect duration for psoriasis treatmentsKenneth B Gordon, Steven R Feldman, John Y M Koo, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Common and Not-So-Common Comorbidities of PsoriasisM Alan Menter, April W Armstrong, Kenneth B Gordon, et al.
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Archives of Dermatology|December 17, 2003
Severe hidradenitis suppurativa treated with infliximab infusionDavid R Adams, Kenneth B Gordon, Attila G Devenyi, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseGerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.
Blood|May 3, 2002
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cellsAnn M Girvin, Kenneth B Gordon, C Jane Welsh, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Seminars in Cutaneous Medicine and Surgery|July 27, 2017
Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™Kenneth B Gordon, Craig L Leonardi, Daniel E Furst, et al.
Archives of Dermatology|January 19, 2005
Definitions of measures of effect duration for psoriasis treatmentsKenneth B Gordon, Steven R Feldman, John Y M Koo, et al.
Pageof 14